ATS: American Thoracic Society International Conference

Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.

Mild asthma could be better treated with the recent approval of the combination of albuterol/budesonide.

Developments in artificial intelligence (AI) can help clinicians to diagnose thoracic conditions that may be miss on first glance.

The value of the combination of albuterol/budesonide is high due to its alleviating of corticosteroid burden, according to Reynold Panettieri Jr, MD.

The landscape of treatment for bronchiectasis could change significantly with the approval of brensocatib, offering a more direct method of stemming the adverse events related to the condition, explains James Chalmers, MD, University of Dundee.

Different dosages of brensocatib proved effective in treating people living with bronchiectasis when studied in the ASPEN trial.

The pulmonary arterial hypertension (PAH) drug preserved its safety profile at 2.5 years of treatment and continued to reduce mortality compared with placebo.

The approval of brensocatib for use in patients with bronchiectasis could offer the first treatment directly addressing the roots of the condition.

Findings from surveys of women with pulmonary arterial hypertension (PAH) include that 20% of health care providers were viewed as dismissive because of the patient’s sex.

Pediatric research explored environmental interventions for bronchiolitis, heart function in children born preterm, and a quality initiative that improved rounding autonomy for pediatric fellows.

Attendees at the American Thoracic Society (ATS) 2025 International Conference highlight global networking, scientific advancements, and professional development at this year's meeting.

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of life in patients with eosinophilic chronic obstructive pulmonary disease (COPD).

Nerandomilast significantly slowed lung function decline and reduced mortality in patients with progressive pulmonary fibrosis (PPF), with consistent efficacy regardless of background antifibrotic therapy.

Toby Maher, MD, PhD, professor of clinical medicine, Keck School of Medicine at USC, shares trial findings from the FIBRONEER-IPF (NCT05321069) and FIBRONEER-ILD (NCT05321082) studies on nerandomilast.

Researchers are working to redefine diagnosis and treatment with data-driven tools aimed at identifying patients earlier and guiding precision care.

Matthew Viggiano, MD, internal medicine resident, Temple University Hospital, shares findings on a study in which female patients with interstitial lung disease (ILD) admitted to the intensive care unit (ICU) experienced significantly lower mortality rates and shorter hospital stays than male patients with ILD.

Krunal Patel, MD, pulmonary and critical care fellow, Temple University Hospital, discusses how early intervention within 12 hours improved hemodynamic measurements and clinical outcomes in patients with pulmonary embolism.

M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill, shares promising results of ensifentrine in helping patients with insufficient chronic obstructive pulmonary disease (COPD) control.

The latest results from the phase 3 FIBRONEER-IPF trial showed consistent benefit of nerandomilast in patients with idiopathic pulmonary fibrosis (IPF) whether or not they were receiving background antifibrotic therapy.

Research presented at the American Thoracic Society (ATS) 2025 International Conference used FDA-approved tools to see how sleep can impact other parts of recovery for patients in the intensive care unit (ICU).

Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia, discusses the value of the win ratio approach in evaluating treatment effects in chronic obstructive pulmonary disease (COPD).

Solutions depend on listening to individuals with lived experience, rebuilding trust, and recognizing the humanity of every patient, experts say.

Michael Goulet, DO, pulmonary and critical care fellow, Temple University Hospital, shares findings on the impact of wildfire smoke on hospital admissions and health care utilization in the Northeast.

Late-breaking findings on pulmonology, critical care, and sleep medicine will be presented at the American Thoracic Society (ATS) 2025 International Conference.

Sandeep Sahay, MD, FCCP, director of the Pulmonary Hypertension Program, Houston Methodist Hospital, previews key topics of this year's American Thoracic Society (ATS) conference.

The top 5 most-viewed content from this year's American Thoracic Society (ATS) 2024 International Conference featured an interview with Monica Kraft, MD, ASTF, and coverage of multiple respiratory and pulmonary medicine areas.

Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, outlines future steps for the clinical development of rilzabrutinib, as well as promising data to advance to phase 3 studies.

Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, discusses efficacy outcomes in patients with asthma who received rilzabrutinib.

The ENV-101 phase 2a trial for idiopathic pulmonary fibrosis (IPF) focused on assessing safety, lung function, and fibrosis, with plans for further trials, combination therapies, and strategies to manage adverse effects.

John Hood, PhD, cofounder and CEO of Endeavor BioMedicines, explains the potential advantages of ENV-101 during a time with very few treatments for idiopathic pulmonary fibrosis (IPF).